Led · Equity · Jun 2024

RareCyte is a Seattle-based precision biology company that designs, manufactures, and markets end-to-end integrated platforms including instruments, reagents, software, and services. Its core product is the Orion spatial biology platform, adopted worldwide to address translational market requirements from discovery to clinical trial support. Orion enables rapid sub-cellular scanning and analysis of tissue and blood samples for up to 20 biomarkers with turn-around times that support large cohort studies. The platform includes a broad array of validated biomarkers for immediate use across immuno-oncology, immunology, neurology, infectious disease, and other areas. RareCyte plans to use the $20M financing to expand the Orion platform by commercializing new multiplex assays, reagent products, and software applications. The funding will also support expansion of its Precision Biology Services, including spatial biology and liquid biopsy assays performed in its Seattle labs under CLIA and ISO 13485 certifications. Led by Joe Victor, President and CEO, RareCyte targets discovery, translational, and future clinical markets with integrated solutions. RareCyte is a life sciences company offering Precision Biology™ solutions focused on multiplexed analysis of cells and tissue for research and clinical diagnostics. The company develops and manufactures platforms, instruments and consumables, including its new Orion spatial biology platform. Leadership is led by President and CEO Joe Victor, and company founder Ron Seubert remains involved. RareCyte says its systems are used in labs worldwide and it has deep experience in advanced precision life science systems. The company raised financing to accelerate commercialization and applications for the Orion platform and to support further global expansion of its portfolio. The reported financing totaled $24M and included both new and existing investors. RareCyte offers an instrument-and-consumables platform for high-resolution multiplex analysis of rare cells in blood and tissue, including AccuCyte Sample Preparation, RarePlex Staining Kits, CyteFinder Instruments, and the CytePicker Retrieval Module. The platform leverages microscope slides to fit into clinical laboratory workflows and supports high-throughput processing and up to seven immunofluorescent biomarker channels for deeper phenotypic analysis. Its integrated retrieval capability enables single-cell phenotype and genotype dataset generation for translational and clinical research. Customers include academic medical institutions and biopharma companies using the system to study complex diseases such as cancer and to support precision-medicine programs. Led by President and CEO Joe Victor and based in Seattle, the company serves preclinical through clinical research markets. RareCyte is a Seattle, WA-based company that develops an integrated rare cell detection and liquid biopsy platform. Its core product lines—AccuCyte and CyteFinder—use standard microscope slides to fit into clinical lab workflows and enable high-throughput processing of blood samples for pre-clinical research and clinical applications. CyteFinder can analyze up to six biomarker channels using immunofluorescent staining for deeper rare cell phenotype analysis, and the CytePicker retrieves single cells to build unique phenotype and genotype datasets at the single-cell level. The platform has been adopted by academic medical institutions and biopharma companies. The company will use the financing to advance commercial sales, build companion diagnostics (CDx) programs with strategic partners, and expand its regulatory infrastructure and research and development efforts. In conjunction with the financing, leadership changes include Joe Victor joining as President and CEO while current CEO Ron Seubert transitions to CTO. RareCyte, founded in 2009 and headquartered in Seattle, develops the AccuCyte System, a rare cell characterization and retrieval platform built on proprietary whole blood enrichment technology. The AccuCyte platform targets circulating tumor cells (CTCs) and circulating endothelial cells (CECs) using an unbiased approach intended to deliver high recovery and purity for downstream analyses. The system is presented as an open platform for life sciences research, drug development, and diagnostic markets, with applications in oncology and cardiovascular disease. AccuCyte is undergoing final testing at RareCyte’s Seattle headquarters through clinical research partnerships. RareCyte plans to use the recently closed tranche of funding to complete final product development and initiate a commercial launch into the research oncology market. Company leadership emphasizes the platform’s role in identification, characterization, enumeration, and retrieval of rare blood cells to aid understanding, diagnosis, and treatment.

Participated · Series A · Sep 2022

Dame Products makes sexual wellness products across about 30 SKUs, including vibrators, gummies and serums; roughly 40% of its products are non-vibrators. The company is launching Dip, a $49 vibrator positioned as an entry-level, inclusive product, on October 12. Dame was founded in 2014 by CEO Alexandra Fine and was profitable and bootstrapped until December 2020. Since its seed raise the company has launched multiple new products, secured retail distribution (Sephora, Bloomingdale’s, Nordstrom, Free People) and settled to run ads on the New York subway. Dame says it has doubled revenue, customers and employees each year for the past two years. Management plans to use the new funding to expand product lines (especially replenishables), invest in product innovation, build content and community, and grow retail and retention efforts.

Led · Equity · Sep 2022

Pathway Power develops utility-scale hybrid solar and battery energy-storage system (BESS) projects purpose-built for large load customers, utilities, and grid operators. Founded in 2022 and headquartered in San Diego, the company's pipeline comprises 13 hybrid and BESS projects totaling approximately 3.2 GWac across the U.S. Its management team has completed over 70 mergers and acquisitions and developed 40 GW of projects over the prior two decades. The company recently secured a $150 million senior-secured financing facility from funds managed by AB CarVal and closed a concurrent separate equity investment to advance late-stage development and construction needs. Use of proceeds includes interconnection, PPAs, equipment deposits, and pre-construction and construction equity costs. Pathway is targeting projects in RTOs including SPP and MISO to serve load growth from data centers and reshoring.